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Previous reports from our lab had shown that sera obtained from SIVmac-infected animals neutralized SIVmac infectivity in
CD41 T cells but failed to protect monkey primary macrophages from infection with the virus. However, the antibodies could
inhibit completion of the viral life cycle in the macrophages at the postentry stage(s). In this report we examined the
mechanisms of the late effect of the antibodies. Using monoclonal antibodies (MAbs), we demonstrated that only antibodies
to the SIV envelope protein (KK17 and KK42) but not antibody to the viral core protein (FA2) had the same inhibitory effect
as that of the anti-SIV sera. To identify the stage of the viral replication cycle that was inhibited by anti-SIV antibodies in
macrophages, we used various PCR techniques to study viral entry/reverse transcription (by amplifying the viral gag gene),
viral genome nuclear transport (by amplifying 2-LTR circular forms), viral integration (by Alu-PCR assay), and viral protein
expression (by RIPA). We found that in macrophage cultures inoculated with SIVmac251 that were preincubated with
antienvelope MAbs, viral DNA was detected at 8 h postinoculation but the 2-LTR circular forms and integrated viral DNAs
were undetectable, and viral proteins were not expressed in these infected macrophages. These results strongly suggested
that anti-SIV antibodies inhibited SIVmac replication in macrophages by blocking nuclear transport of viral genomes since viral
DNA could not be detected in the nuclei of treated cultures. Furthermore, we showed that although viral replication in
macrophages was interrupted by the antibodies, when cocultured with permissive T cells, the viral genomes presented in the
cytoplasm of the macrophages could readily transfer to T cells during cell–cell contact. Importantly, this transfer could not
be prevented by the antibodies. These results might explain the failure of passive antibody immunization against
SIVmac251—a critical obstacle in AIDS vaccine development. © 2001 Academic Press
Key Words: SIV; HIV; AIDS; antibody; neutralization; nuclear transport; macrophage.
sINTRODUCTION
Neutralizing antibodies that develop during viral infec-
tions usually coincide with the end of the infection and
are important for the prevention of further episodes of
infection. The antibodies are important players in nearly
all successful antiviral vaccines. However, the role of
neutralizing antibodies in modulating the pathogenesis
of lentivirus infection is less clear. In HIV infections, the
presence of such antibodies does not provide prognostic
or predictive indications on the rate of disease progres-
sion. The only definitive correlation is that antiviral im-
mune responses are not produced during rapid-onset
disease. In more slowly progressive infections, neutral-
izing antibodies developing after infection coexist with
productive virus replication (Burton and Montefiori, 1997;
Montefiori et al., 1996). One explanation for this contra-
ictory phenomenon is that viruses under these condi-
ions tend to be neutralizing antibody-escape variants of
he viral quasispecies (Homsy et al., 1990; Joag et al.,
1993; Nara et al., 1990; Albert et al., 1990).1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (913) 588-5599. E-mail: wzhuge@kumc.edu.
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436The discovery that SIV infection in macaques causes
HIV-like disease led to the utilization of the SIV/macaque
model systems to study HIV pathogenesis and host pro-
tective immunological mechanisms (Benveniste et al.,
1988; Kestler et al., 1990). The SIV/macaque system,
however, yielded conflicting results in prophylactic pas-
sive immunization experiments that examined the role of
neutralizing antibodies in protective immunity. Whereas
the passive immunization failed to prevent infection with
different strains of SIVmac (251, 239, and J5M) (Gardner et
al., 1995; Kent et al., 1994; Almond et al., 1997), the
trategy was successful when progeny of SIVSM strains
(SMM-3, B670, etc.) or SIVmne were used (Biberfeld et al.,
1992; Putkonen et al., 1991; Clements et al., 1995; Lewis
et al., 1993; Haigwood et al., 1996). These conflicting
passive immunization results become a major problem
in understanding the protective immunities against HIV
and in the AIDS vaccine development. The question that
needs to be answered is, therefore, what are the deter-
minants of the success or failure of prophylactic passive
immunization?
Based on the fact that all SIVmac strains were derived
from a common origin (Schultz and Hu, 1993), we hypoth-
esized that the failure of passive immunization against
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437NEUTRALIZING MAbs BLOCK NUCLEAR TRANSPORT OF SIVmac251strains of SIVmac might stem from unique neutralization
characteristics that are peculiar to SIVmac. We attempted
o answer this question by using two strains of SIVmac
(251 and 239). Proceeding on the background that the
prophylactic passive immunization against these viruses
failed, we asked whether the antisera would neutralize
the viruses in both of the target cell types (i.e., CD41 T
lymphocytes and macrophages) used by the virus in vivo.
These experiments showed that CD41 T cells (either
mmortalized T cell lines or macaque PBMCs) could
ndeed be protected from SIVmac infection by neutralizing
antibodies (Zhuge et al., 1997, 1998). When virus, prein-
cubated with the neutralizing antibodies, was inoculated
into macrophage cultures, productive replication of the
virus was also prevented, as judged by lack of viral p27
production (Zhuge et al., 1997). This led to the early
conclusion that neutralization was successful. However,
later studies showed that macrophages inoculated with
preincubated virus–antibody mixtures developed PCR
signals for viral DNA. Even more disturbing, although the
antibodies prevented infection in CD41 T cells and in-
hibited viral replication in macrophages, they failed to
prevent the spread of infection from the macrophages to
CD41 T cells when the latter were added to the “latently”
nfected macrophages in the presence of the antibodies
Zhuge et al., 1998). The infection spread rapidly to the T
ells in this coculture environment. Thus, whereas the
ntibodies prevented infection in T cells with cell-free
irus, they could not prevent infection mediated by “la-
ently” infected macrophages. The pseudo neutralization
f SIVmac (251 and 239) in macrophages has not been
observed before and its mechanisms are poorly under-
stood. In two previous reports on this phenomenon, poly-
clonal antiviral sera obtained from infected macaques
had been used in all neutralization experiments. Whether
the antibody-mediated inhibition of SIVmac replication in
macrophages was due to antiviral or anticellular antibod-
ies was not clear.
In this study, by using various anti-SIV monoclonal
antibodies, we investigated the mechanism(s) by which
neutralizing antibodies inhibit SIVmac replication in mac-
ophages. Our data suggested that antiviral envelope
onoclonal antibodies, after binding to the virus, did not
revent the entry of virus into macrophages. Instead, the
ntibodies apparently blocked nuclear import of the viral
NA in the infected macrophages.
RESULTS
ntibody-mediated inhibition of SIVmac251 replication
n macrophages is due to antiviral envelope
ntibodies
In previous reports we showed a phenomenon of dif-
erential neutralization of SIVmac in lymphocytes and mac-
ophages by using polyclonal anti-SIV sera obtained
rom infected macaques (Zhuge et al., 1997). Whether thentibody-mediated inhibition of SIVmac replication in mac-
ophages was due to antiviral or anticellular antibodies
n the postinfection sera was not clear. In this experi-
ent, two anti-SIV envelope neutralizing monoclonal an-
ibodies (MAbs), KK17 and KK42, were used in the neu-
ralization assays. It has been reported that KK42 binds
o V3 (aa 321–340) of the SIVmac envelope and has a low
neutralizing titer against SIVmac251 in T cells, while KK17
inds to a conformational epitope on gp120 of the SIVmac
envelope and has strong neutralizing activity against
SIVmac251 (Kent et al., 1992, 1991; Choi et al., 1994). In
reliminary experiments, we found that both MAbs neu-
ralized the infectivity of SIVmac251 effectively at a con-
entration as low as 0.1 mg of MAb in 200 ml of reaction
mixture when tested on normal rhesus macaque macro-
phage cultures (data not shown). A tested nonneutraliz-
ing anti-Gag MAb, FA2, was used as a control. To inves-
tigate whether these MAbs prevent infection of SIVmac251,
we used 100, 10, 1, or 0.1 TCID50 of DNase-treated
SIVmac251 to preincubate with 10 mg of either KK17, KK42,
or FA2 in a total volume of 200 ml for 1.5 h at 37°C and
then inoculated the mixtures into cultures of T cells
(CEM 3 174) or monkey primary macrophages. Twenty-
four hours later, cultures were washed and total cellular
DNA was extracted. A PCR-based assay to amplify the
viral gag gene was performed to determine whether the
cells were infected. Results showed that both KK17 and
KK42 blocked SIVmac251 infection in T cells, while FA2 did
not (Fig. 1A). When macrophage cultures were used as
the target cell, however, the two MAbs were unable to
block infection of SIVmac251 in macrophages as judged
y the presence of viral DNA in the cultures (Fig. 1B).
owever, as indicated in radio-immunoprecipitation as-
ays (RIPA), no viral proteins were produced at 7 days
ostinoculation in the infected macrophages that were
noculated with virus preincubated with KK17 or KK42
Fig. 2, lanes 1 and 2). These results suggested that
neutralization of SIVmac251” in macrophages occurred at
post viral entry stage instead of blocking viral entry.
hese results confirmed our previous reports where
olyclonal antiviral sera were used and demonstrated
urther that the phenomenon was mediated by anti-SIV
nvelope antibodies.
nti-SIV envelope MAb delayed SIVmac251 entry into
acrophages
To compare the time course of entry of various anti-
ody-treated SIVmac251 into macrophages, we inoculated
acrophages with 10 TCID50 of SIVmac251 preincubated
with 1 mg of either KK17 or FA2. At 1, 2, 4, 8, and 24 h
ostinoculation, macrophage cultures were washed and
NAs extracted and subjected to PCR amplification of
he viral gag gene. As shown in Fig. 3, viral DNA readily
became detectable in macrophages at 2 h postinocula-
tion with SIVmac251 preincubated with nonneutralizing
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438 ZHUGE ET AL.MAb FA2. In the cultures inoculated with SIVmac251 pre-
ncubated with MAb KK17, however, viral DNA was not
etected until 8 h postinoculation. There are two possi-
le explanations for this result. One is that the viral entry
r reverse transcription process was interrupted and/or
ltered by KK17 so the appearance of viral DNA was
elayed. The other was that some viral particles became
issociated from the neutralizing MAb KK17, entered the
ells, and initiated infection. Given either of the two
ossibilities, it was remarkable that the later stages of
he viral life cycle were blocked by the neutralizing anti-
odies.
nti-SIV MAbs blocked nuclear import of viral
enomes
Since the neutralizing MAbs were unable to block
IVmac251 entry into macrophages but inhibited its repli-
ation, which is similar to the effect of polyclonal anti-SIV
era, we sought to identify the stage of the viral life cycle
n macrophages that was blocked by the antibodies.
ince we amplified the viral gag gene, a product of late
tage viral reverse transcription, this suggested that viral
everse transcription had occurred after the virus entered
he macrophage. The next question was whether viral
NA had been transported into the nucleus. We used
ested PCR to detect the 2-LTR circular form of SIVmac
DNA, which is an indication of the presence of viral
genomes in the nucleus (Stevenson et al., 1990). Macro-
phage cultures inoculated with 10 TCID50 of SIVmac251
reincubated with serially 10-fold-diluted anti-Env KK17,
K42, or anti-Gag MAb FA2 (10, 1, 0.1, and 0.01 mg of MAb
in 200 ml, respectively) were washed and subjected to
DNA extraction at 24 h pi. Nested PCRs amplifying either
SIV gag or 2-LTR circular viral DNA from 200 ng of total
NA were performed as described under Materials and
ethods. Results showed that viral gag was amplified
FIG. 1. Neutralizing anti-Env MAbs failed to block SIVmac251 entry int
, 0.1 TCID50) were preincubated with 10 mg of anti-Gag MAb FA2, anti-
were inoculated onto T cells (CEM 3 174) or primary macrophages. Tw
CR assay to amplify the viral gag gene. Panel A shows the results from
ontrol.rom all the macrophage cultures inoculated with SIV-
mac251 preincubated with FA2, KK17, or KK42 antibodiesegardless of the MAb concentrations (Fig. 4A). The
-LTR circular form of viral DNA was detected in the
acrophage cultures inoculated with SIVmac251 preincu-
bated with FA2 (Fig. 4B, lanes 1–3), but not in the cultures
inoculated with virus that was preincubated with 10, 1, or
0.1 mg of neutralizing MAb KK17 or KK42, respectively
(Fig. 4B, lanes 4–6 and 8–10). These results suggested
that the viral genomes had not been transported into the
nucleus in the presence of the neutralizing MAbs.
Although the presence or the absence of the 2-LTR
circular form of viral DNA has been used by most inves-
tigators as an indicator of the nuclear import of viral
genome (Stevenson et al., 1990; Pancio et al., 2000;
chmidtmayerova et al., 1998), we extended the study to
etermine whether integration of the viral genome had
ccurred. We employed an Alu-PCR assay to detect in-
egrated viral DNA. Results showed that integrated viral
NA was undetectable in macrophages inoculated with
IVmac251 preincubated with down to 0.1 and 0.01 mg of
K17 or KK42 (Fig. 4C, lanes 4–6 and 8–10), but was
etectable in macrophage cultures inoculated with virus
reincubated with FA2 (Fig. 4C, lanes 1–3).
iral genomes harbored in the macrophages could be
ransferred to permissive T cells by cocultivation but
equire cell–cell contact
We had reported previously that macrophages harbor-
ng SIVmac239 could disseminate the virus to T cells upon
cocultivation even in the presence of neutralizing anti-
body (Zhuge et al., 1998). But it is unclear how the
process occurred. In this experiment, we used the trans-
well culture system to dissect the phenomenon of
spread. SIVmac251 (100 TCID50) was preincubated with 1
mg of KK17 or FA2 at 37°C for 1.5 h, and the virus/
antibody mixtures were inoculated into rhesus macro-
phage cultures in 6-well plates. After overnight incuba-
ophages. Various concentrations of DNase-treated SIVmac251 (100, 10,
b KK17, or anti-Env MAb KK42 at 37°C for 1.5 h and then the mixtures
ur hours later, cultures were washed and the DNA was extracted for
and panel B macrophage cultures. Pos, positive control; Neg, negativeo macr
Env MA
enty-fotion, the cultures were washed five times to remove
inocula, and the cultures reincubated with fresh medium
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439NEUTRALIZING MAbs BLOCK NUCLEAR TRANSPORT OF SIVmac251containing same amount of MAb. One day later, the
cultures were washed again and replenished with the
same medium/MAb. One million T cells (CEM 3 174
cells) were then added either directly into each well
containing macrophage cultures (permitting cell–cell
contact) or indirectly into 1-mm transwell chambers in-
FIG. 2. Radio-immunoprecipitation assay (RIPA) to measure viral
protein synthesis in macrophages. Ten TCID50 of SIVmac251 was prein-
cubated with 1 mg of anti-Env MAb KK42, KK17, or anti-Gag MAb FA2 at
7°C for 1.5 h and then the mixtures were inoculated onto macrophage
ultures in 6-well plates. At 6 days postinoculation the macrophage
ultures were washed and then radiolabeled with [35S]methioline for
8 h and the cell lysates were prepared and subjected to RIPA to
mmunoprecipitate newly synthesized viral proteins as described pre-
iously. Lane 1, macrophages inoculated with 10 TCID50 of SIVmac251
hat was preincubated with 1 mg of anti-Env MAb KK42. Lane 2,
macrophages inoculated with 10 TCID50 of SIVmac251 that was preincu-
ated with 1 mg of anti-Env MAb KK17. Lane 3, macrophages inoculated
ith 10 TCID50 of SIVmac251 that was preincubated with 1 mg of anti-Gag
MAb FA2. Lane 4, uninfected macrophages.serted into the macrophage cultures to prevent cell–cell
contact. The cultures were monitored for cytopathic ef-fect (CPE) and culture supernatants were collected at
sequential time points for RT assay. CPE and RT activi-
ties developed after CEM 3 174 cells were added di-
rectly or indirectly into macrophage cultures that were
inoculated with SIVmac251 preincubated with FA2. In the
macrophage cultures that were inoculated with
SIVmac251 preincubated with neutralizing MAb KK17, CPE
nd RT activities developed only after CEM 3 174 cells
ere added directly into the macrophage cultures but
ot into the transwell chambers in which the two cell
ypes were separated. The RT activities reached similar
xtension in both macrophage cultures that had CEM 3
74 cells added directly into the wells regardless of
hich MAb was used (Fig. 5). We then asked whether a
imilar macrophage–T-cell transfer of SIVmac251 would
ccur if a coculture of these macrophages with primary
hesus PBMCs instead of cell line T cells (CEM 3 174)
as done. To address this question, similarly treated
acrophage cultures as described above were set up.
fter extensive wash as described, the same amounts of
Abs were added back to the culture medium, and 2 3
06 PHA-activated rhesus PBMCs were then added to
each well to coculture with the macrophages. Culture
supernatants were collected for RT assay. As shown in
Fig. 6, primary rhesus PBMCs, similar to CEM 3 174
cells, were readily infected if cocultured with macro-
phages that were inoculated with either antibody (FA2 or
KK17)-treated SIVmac251, and this process is not pre-
ented by the presence of neutralizing antibody (KK17) in
he culture medium. These macrophage–T-cell transfer
esults gave additional evidence showing that neutraliz-
ng MAb KK17 failed to block SIVmac251 entry into mac-
ophages and further demonstrated that viral genomes
arbored in such antibody-treated macrophages were
nfectious and could be transferred to permissive T lym-
hocytes via cell–cell contact.
DISCUSSION
In the present study, by using anti-SIV monoclonal
ntibodies, we have extended our previous reports that
ntisera obtained from SIV-infected animals were unable
o block the entry of SIVmac into macrophages but inhib-
ited its replication in the cells. We have demonstrated
here that (1) antienvelope antibody contributes to the
phenomenon of antibody-mediated inhibition of SIVmac
replication in macrophages; (2) this inhibiting effect is
due to the ability of antibody to block nuclear import of
the viral genome in infected macrophages; and (3) the
macrophage-harbored viral genome could be transferred
to T cells but requires cell–cell contact, and this macro-
phage–T-cell transfer process cannot be prevented by
neutralizing antibody.
We tested three MAbs in this study: two antienvelope
MAbs (KK17 and KK42) and one anti-Gag MAb (FA2). We
found that only antienvelope MAbs have the ability to
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440 ZHUGE ET AL.inhibit the SIVmac replication in macrophages, while the
anti-Gag MAb has no neutralizing effect. It has been
reported that KK42 binds to V3 (aa 321–340) of the SIVmac
envelope and has a low neutralizing titer against
SIVmac251 in T cells, while KK17 binds to a conformational
pitope on gp120 of the SIVmac envelope and has strong
eutralizing activity against SIVmac251 (Kent et al., 1992,
1991; Choi et al., 1994). Consistent with these reports, we
also demonstrated that both KK17 and KK42 blocked the
entry of SIVmac251 into T cells. In the contrast, when the
same neutralization assay was tested on macrophages,
we found that both anti-Env MAbs failed to block viral
entry into macrophages but nevertheless inhibited viral
replication at high titers.
Proceeding on the conclusion that antibodies blocked
the SIVmac251 replication cycle at a postentry stage in
acrophages, we next attempted to identify the stage of
he viral life cycle where the blockage occurred. We
ddressed the question in this study by investigating
arious stages of the viral life cycle, including viral re-
erse transcription, transportation of the viral preintegra-
ion complex into the nucleus, viral DNA integration, and
roduction of viral proteins in the infected macrophage
ultures. Our results showed that, after incubation with
eutralizing MAbs, SIVmac251 entered macrophages and
FIG. 3. Anti-Env MAb delayed SIVmac251 entry or the reverse tran
SIVmac251 that was preincubated with 1 mg of either anti-Gag MAb FA
cultures were washed and DNAs extracted and subjected to PCR amp
FIG. 4. Anti-Env MAbs blocked nuclear import of SIVmac251 DNA in m
1, 0.1, or 0.01 mg of anti-Gag MAb FA2, or anti-Env MAb KK17, or KK42 a
At 24 h postinoculation, the macrophage cultures were washed and
circular viral DNA, or integrated viral DNA(Alu-PCR) from 200 ng of total DNA w
show in A the viral gag gene; in B, the 2-LTR circular form of viral DNA; andompleted reverse transcription, but the 2-LTR circular
orms of viral DNA, which are a hallmark of the presence
f the viral genome in the nucleus, were absent. Further,
here was no evidence of viral DNA integration or pro-
uction of viral proteins. These data strongly suggested
hat antibodies blocked the nuclear transport of viral
NA from the cytoplasm of infected macrophages.
The question of why the neutralizing antibodies were
nable to block SIVmac251 entry into macrophages while
hey completely blocked entry of the same virus into T
ells remains unsolved. In a previous report, we had
xcluded the obvious suspicion that infection in macro-
hages was mediated by Fc receptor-medicated endo-
ytosis of antibody-bound virus because the identical
equence of events occurred when the Fab was used
nstead of the intact neutralizing IgG (Zhuge et al., 1997).
further question is how could antienvelope antibodies
lock nuclear import of the viral genome in macro-
hages? We speculate that antibodies might have inter-
ered with signal transduction upon binding of the viral
nvelope to its receptors (CD4 and CCR5 for SIVmac). It
as been reported that upon binding to receptors, enve-
ope proteins derived from M-tropic HIV-1 and SIVmac
triggered a calcium influx into macrophages, while en-
velopes derived from non-M-tropic viruses did not
n process. Macrophage cultures were inoculated with 10 TCID50 of
ti-Env MAb KK17. At 1, 2, 4, 8, and 24 h postinoculation, macrophage
on of the viral gag gene.
hages. Ten TCID50 of DNase-treated SIVmac251 was incubated with 10,
for 1.5 h. The mixtures were then inoculated into macrophage cultures.
ed to DNA extraction. Nested PCRs amplifying either SIV gag, 2-LTRscriptioacrop
t 37°C
subjectere performed as described under Materials and Methods. PCR results
in C, the integrated viral DNA by Alu-PCR.
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441NEUTRALIZING MAbs BLOCK NUCLEAR TRANSPORT OF SIVmac251(Weissman et al., 1997; Arthos et al., 2000). It is more
intriguing that although CCR5-utilizing non-M-tropic
HIV-1 was capable of entering macrophages, its replica-
tion cycle was blocked due to lack of signaling. However,
productive replication of this non-M-tropic HIV-1 oc-
curred in macrophages after the addition of MIP-1a,
indicating that a CC chemokine-mediated signal through
CCR5 provided the necessary stimulus to allow the virus
to complete its life cycle (Arthos et al., 2000). Based on
those findings, we hypothesize that after binding to virus,
an antibody may block the CC chemokine-mediated sig-
nal so although virus gets into the cells, its life cycle at
the stage of nuclear import of viral DNA is blocked. The
other possibility is that antibodies were internalized with
bound virus, prevented subsequential viral uncoating,
and interfered with the formation of the preintegration
complex or transportation of the preintegration complex
to the nucleus.
In humans, infection is presumed to be mediated by an
M-tropic HIV-1 (Schuitemaker et al., 1992; Zhu et al.,
1993). It is well known that most HIV-1 patient isolates
utilize CCR5 as coreceptor for viral entry (Zhang et al.,
1998), and they are more resistant to neutralizing anti-
bodies than laboratory-adapted strains (Moore et al.,
1995; Hioe et al., 1997; Mascola et al., 1997; Parren et al.,
1998; Cecilia et al., 1998). We reported previously that
FIG. 5. SIVmac251 genomes harbored in the macrophages could be t
CID50 of SIVmac251 was preincubated with 1 mg of either KK17 or FA2 f
macrophage cultures in 6-well plates. After overnight incubation, th
reincubated with fresh medium containing the same amount of MAb. O
medium/MAb; 1 3 106 of T cells (CEM 3 174 cells) were added either
or indirectly into 1-mm transwell chambers inserted into the macrop
collected at 0, 3, 5, and 7 days after T cell addition for RT assay.entries of both HIV-1 Bal and 89.6 strains into either T
cells or macrophages were blocked by neutralizing an-
Stibodies (Zhuge et al., 1998). Although both strains of
HIV-1 were considered primary isolates by many inves-
tigators, they were passed many times in various labo-
ratories so they might behave more like lab-adapted
strains. Therefore we still want to ask, does neutraliza-
tion of patient isolates of HIV-1 in human macrophages
behave similarly to the pseudo-neutralization of
SIVmac251? We ask this because Ruppach et al. recently
reported that antisera obtained shortly after HIV-1 infec-
tion inhibited the output of autologous HIV-1 primary
isolates differently in inoculated human macrophages
than in T cells (Ruppach et al., 2000), a phenomenon very
similar to the neutralization of SIVmac251 in monkey mac-
ophages we had reported. In this recent report, Rup-
ach et al. tested 10 strains of primary HIV-1 isolates,
ncluding 6 strains of subtype B, 1 strain of subtype C,
nd 3 strains of subtype E. It will be very interesting to
nvestigate whether antibodies could block the entry of
hose HIV-1 primary isolates into human macrophages
nd whether virus could be rescued by coculture with T
ells, as seen in the SIV studies.
It has been a puzzle for many years why passive
dministration of neutralizing antibodies failed to pro-
ect animals from SIVmac251 infection (Gardner et al.,
995; Kent et al., 1994), while the same strategy was
ery successful in preventing infections with SIVSM,
red to CD41 T cells by cocultivation but require cell–cell contact; 100
at 37°C, and the virus/antibody mixtures were inoculated into rhesus
res were washed five times to remove inoculum, and the cultures
later, the cultures were washed again and replenished with the same
y into each well of macrophage cultures (permitting cell–cell contact)
ultures (to prevent cell–cell contact). The culture supernatants wereransfer
or 1.5 h
e cultu
ne day
directlIVmne, SHIVKU, SHIV89.6P, and some HIV-1 strains (Bib-
erfeld et al., 1992; Lewis et al., 1993; Foresman et al.,
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442 ZHUGE ET AL.1998; Mascola et al., 1999, 2000; Eichberg et al., 1992;
mini et al., 1992). These conflicting results in passive
mmunization trials raised a serious question regard-
ng the role of neutralizing antibody in the host pro-
ective immunities against HIV and the strategy of
IDS vaccine development. One explanation for the
ailure of passive immunization against SIVmac251 is
that SIVmac251 primary stocks grown in PBMCs were
ore resistant to neutralization (Langlois et al., 1998;
eans et al., 1997). Our results presented here and
eported previously could offer another explanation.
e think, due to the failure of neutralizing antibodies
o protect macrophages from infection with
IVmac251 and because of the failure of neutralizing
ntibodies to prevent transfer of the viral genomes
rom macrophages to CD41 T cells, SIVmac251 could
infect macrophage-lineage cells in the bloodstream
following inoculation even in the presence of circulat-
ing neutralizing antibodies, and the virus could spread
rapidly from infected macrophages to permissive
CD41 T cells. In contrast to SIVmac251, it is noteworthy
hat passive admission of neutralizing antibodies suc-
essfully protected animals from infection with either
HIVKU or SHIV89.6P in various animal studies (Fores-
an et al., 1998; Mascola et al., 1999, 2000), and our
arlier report coincidentally showed that neutralizing
FIG. 6. SIVmac251 genomes harbored in macrophages could be transf
preincubated with 1 mg of either KK17 or FA2 for 1.5 h at 37°C, and the
6-well plates. After overnight incubation, the cultures were washed five
containing the same amount of MAb. One day later, the cultures we
macrophage cultures were cocultured with 2 3 106/well of PHA-activate
he culture supernatants were collected at 0, 3, 5, and 7 days after Pntibodies protected both T cells and macrophages
rom infection with SHIVKU and HIV-1 89.6 (from whichthe envelope of SHIV89.6P derived) (Zhuge et al., 1998).
t will be interesting to further identify which property
f SIVmac251 is responsible for the failure of neutraliz-
ing antibody in blocking viral entry into macrophages
and to investigate whether a similar phenomenon oc-
curred in HIV-1 primary isolates. Also, since neutral-
izing antibodies are unable to prevent the cell–cell
spread of virus infection as we demonstrated here, it
would be a big concern in preventing HIV infection
among IV drug users that virus-infected cells are fre-
quently the source of transmission.
In summary, we could show for the first time that
anti-SIV envelope neutralizing monoclonal antibodies
that prevented infection in T cells were unable to block
the entry and reverse transcription of SIVmac251 in mac-
ophages. Our data suggested strongly that antibody-
ediated inhibition of the SIVmac251 life cycle occurred at
the stage of nuclear transport of the viral DNA. Never-
theless, the viral genomes remained infectious in the
macrophage and could readily be transferred to T cells
upon contact even in the presence of the neutralizing
MAbs. These results provide an explanation of why pro-
phylactic passive immunization failed to protect animals
from SIVmac251 infection. Further studies of the mecha-
nisms of antibody-mediated inhibition of virus replication
o primary rhesus PBMCs by cocultivation; 100 TCID50 of SIVmac251 was
ntibody mixtures were inoculated into rhesus macrophage cultures in
to remove inoculum, and the cultures reincubated with fresh medium
hed again and replenished with the same medium/MAb. Half of the
s PBMCs and the other half without PBMC addition served as controls.
ddition for RT assay.erred t
virus/a
times
re wasin macrophages will provide valuable information for
better understanding of host protective immunities
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MATERIALS AND METHODS
Cells
CEM 3 174 cells were cultured at a concentration of
about 0.5–1 3 106/ml in RPMI 1640 supplemented with
10 mM HEPES buffer, pH 7.3, 50 mg/ml gentamicin, 5 3
1025 M 2-mercaptoethanol, 2 mM glutamine (together
aking serum-free RPMI or sRPMI), and 10% fetal bovine
erum (the complete medium called R10FBS).
Normal SIV-negative rhesus monkey PBMCs were
eparated from buffy coat cells by centrifugation through
icoll–Hypaque density gradients. For making activated
BMCs, the separated PBMCs were cultured at a density
f 2 3 106/ml in R10FBS and stimulated with 1 mg/ml
PHA for 2 days. After PHA stimulation, the PBMCs were
washed and maintained in R10FBS supplemented with
100 U/ml of rIL-2 (Cetus). For rhesus primary macro-
phage cultures, the separated PBMCs were seeded into
6- or 12-well plates (at a concentration of 6 3 106 or 3 3
106 cells/well, respectively) with macrophage differenti-
ation medium (MDM), which consisted of sRPMI supple-
mented with 10% human serum, 5 units/ml of macro-
phage colony-stimulating factor (M-CSF, Genetics Insti-
tute), and 100 units/ml of granulocyte macrophage
colony-stimulating factor (GM-CSF, Genetics Institute).
Macrophages were obtained after 7–10 days of cultiva-
tion with extensive washes and three medium changes.
Virus and antibodies
SIVmac251 is a biologically cloned pathogenic M-tropic
irus. Virus stock was obtained by inoculating the agent
nto CEM 3 174 cells at m.o.i.s of approximate 0.01 and
arvesting the culture supernatant fluids 7 days later by
entrifugation at 2000 rpm for 10 min. Virus stock was
liquoted and stored at 280°C until use. The infectious
iter of virus stock was measured using methods previ-
usly described (Joag et al., 1993).
Three monoclonal antibodies were used in this study.
wo anti-SIVmac envelope MAbs, KK17 (IgG2a) and KK42
IgG1), and an anti-SIVmac Gag MAb, FA2 (IgG2b), were
obtained from the NIH AIDS Research and Reference
Reagent Program. The properties of these antibodies
had been described previously (Kent et al., 1992, 1991;
Choi et al., 1994; Sutjipto et al., 1990).
Virus neutralization assays
Virus neutralization assays were performed as previ-
ously described with some modifications (Zhuge et al.,
1997). Generally, unless stated specifically, twofold dilu-
tions of antibody were incubated with 100 TCID50 of
SIVmac251 in a total volume of 0.2 ml for 1.5 h at 37°C, and
he virus–antibody mixtures inoculated into indicator
A
wells (about 1 3 105 cells in 1 ml/well) cultured in 6-well
lates. Inoculated cultures were incubated for 5–7 days.
ultures were then washed five times with 5 ml of se-
um-free medium, replenished with culture medium with-
ut the antibody, and reincubated at 37°C. Culture su-
ernatant fluids were then collected after overnight in-
ubation and examined for content of viral reverse
ranscriptase activities (RT assay) and the 90% neutral-
zation end point was calculated. In some experiments,
roductive viral replication was examined by using RIPA
s described previously (Zhuge et al., 1997).
etection of viral genome using PCR
Virus stock was first filtered through a 0.22-mm filter
and then treated with 136 Units of DNase I (GIBCO BRL)
in a volume of 1 ml for 15 min at 25°C. DNase-treated
virus stocks tested negative for viral DNA by PCR de-
scribed below (data not shown). Various concentrations
of DNase-treated virus were reacted with antibody in a
volume of 400 ml for 1.5 h at 37°C. T cell and macrophage
ultures were then inoculated with equal volumes of the
irus/antibody mixtures (200 ml each) plus 1 ml of addi-
ional medium. One day later (or at stated time points),
he cultures were washed five times with serum-free
edium, cells were lysed in 0.5 ml of lysing buffer (TE
uffer containing 0.05% of SDS), and cellular DNA was
xtracted; 200 ng of each DNA was used in nested PCR
o seek the presence of the SIV gag gene. The oligonu-
leotide primers used for the SIV gag gene amplification
which amplify 240 bp of fragment) were described pre-
iously (Zhuge et al., 1997). PCR amplification was per-
ormed with an automated DNA Thermal Cycler (Perkin–
lmer Cetus) for 35 cycles using the following conditions:
enaturation at 92°C for 1 min, annealing at 55°C for 1
in, and primer extension at 72°C for 1 min. For detect-
ng the 2-LTR circular form of SIV DNA, 200 ng of ex-
racted DNA was used in nested PCR under the same
mplification conditions as described for gag. The first
round PCR primer sets were sense, 59-CACTAGCAGG-
TAGAGCCTGGGTGT-39; anti-sense, 59-GTCATCCCACT-
GGGAAGTTTGAGC-39, which correspond to SIVmac239
equence 10031–10054 and 230–207, respectively
Regier and Desrosiers, 1990). The inner primer sets
ere sense, 59-GCTAGACTCTCACCAGCACTTG-39; anti-
ense, 59-CTCATCCTCCTGTGCCTCATCT-39, which cor-
espond to SIVmac239 sequence 10060–10081 and 185–
64, respectively. Nested PCR was used for Alu-PCR; 200
g of extracted DNA was used in the first round PCR, the
ense primer was 59-TAGTCGGGAGGCTGAGGCAG-
AGAA-39 that corresponds to human Alu sequence
osition 172–196, and the anti-sense primer was 59-
TCATCCCACTGGGAAGTTTGAGC-39, located in the U3
egion (bp 230–207) of SIV LTR. After the first round
lu-PCR, 1 ml of PCR product was used in nested PCR
ith the following primer pair: sense 59-TGGAAGGG-
P
a
7
c
a
e
M
444 ZHUGE ET AL.ATTTATTACAGTGCAAGAAGAC-39 (bp 1–30 of SIVmac239),
anti-sense 59-CTCATCCTCCTGTGCCTCATCT-39 (bp 185–
164 of SIVmac239). The amplification conditions for Alu-
CR were 35 cycles of denaturation at 94°C for 1 min,
nnealing at 55°C for 1 min, and primer extension at
2°C for 3 min. Following the second round of amplifi-
ation, a 10-ml aliquot was removed and run on a 1.5%
garose gel and bands were visualized by staining with
thidium bromide.
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